Genedrive (AIM: GDR), reported finals to June 2021 today and despite its Covid testing product its sales fell to £0.7m from £1.1m. It listed in 2007 and have developed an easy to use effective and efficient testing platform that brings molecular diagnostics to decentralised laboratories. These tests are less time and labour intensive than traditional culture methods and can provide rapid diagnosis.
The shares reached 158p on Covid Testing hopes, but these disappointing figures fell short on expectations as the high throughput SARS-CoV-2 assay product was too late for the US market to benef...
